Grace Therapeutics, Inc.
- GRCE
- NASDAQ
- Biotechnology
- Rare Disease Therapeutics
- Clinical-Stage Biotech
$1.88
Today −0.53%Quote Oct 19, 2026, 08:00 PM UTC
−10.90%over the last month
Max drawdown −13.0%From 1-month high −13.0%3 months −22.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Grace Therapeutics
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
5
Market value
$30.6M
Quote Oct 19
Analyst target
$4.00
+112.8% from here
Floor
$1.85
1.6% below price
Resistance
$1.93
2.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GRCEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free